Quarterly report pursuant to Section 13 or 15(d)

Income Taxes

v2.4.0.8
Income Taxes
6 Months Ended
Mar. 31, 2014
Income Taxes [Abstract]  
Income Taxes

NOTE 9 – Income Taxes

 

The Company accounts for income taxes using the liability method, which requires the recognition of deferred tax assets or liabilities for the tax-effected temporary differences between the financial reporting and tax bases of its assets and liabilities, and for net operating loss and tax credit carryforwards.

 

The Company completes a detailed analysis of its deferred income tax valuation allowances on an annual basis or more frequently if information comes to our attention that would indicate that a revision to our estimates is necessary.  In evaluating the Company’s ability to realize its deferred tax assets, management considers all available positive and negative evidence on a country-by-country basis, including past operating results and forecast of future taxable income.  In determining future taxable income, management makes assumptions to forecast U.S. federal and state, U.K. and Malaysia operating income, the reversal of temporary differences, and the implementation of any feasible and prudent tax planning strategies.  These assumptions require significant judgment regarding the forecasts of the future taxable income in each tax jurisdiction, and are consistent with the forecasts used to manage the Company’s business.   It should be noted that the Company realized significant losses through 2005 on a consolidated basis.  Since fiscal year 2006, the Company has consistently generated taxable income on a consolidated basis, providing a reasonable future period in which the Company can reasonably expect to generate taxable income.  In management’s analysis to determine the amount of the deferred tax asset to recognize, management projected future taxable income for the subsequent ten years for each tax jurisdiction.

   

As of March 31, 2014, the Company had U.S. federal and state net operating loss carryforwards of approximately $19,165,000 and $17,220,000, respectively, for income tax purposes expiring in years 2018 to 2027.  The Company’s U.K. subsidiary, The Female Health Company-UK, plc has U.K. net operating loss carryforwards of approximately $63,264,000 as of March 31, 2014, which can be carried forward indefinitely to be used to offset future U.K. taxable income. With the demand for and profitability of FC2, the Company expects utilization of its net operating losses in both the U.K. and the U.S. will continue.  The U.K. net operating losses do not expire. The Company’s Malaysia subsidiary had no net operating loss carryforwards as of March 31, 2014.  The Company’s net operating loss carryforwards will be utilized to reduce cash payments for income taxes based on the statutory rate in effect at the time of such utilization.

 

A reconciliation of income tax expense and the amount computed by applying the statutory federal income tax rate to income before income taxes for the three and six months ended March 31, 2014 and 2013, is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

March 31,

 

March 31,

 

2014

 

2013

 

2014

 

2013

Income tax expense at statutory rates

$

299,000 

 

$

1,227,000 

 

$

831,000 

 

$

2,437,000 

State income tax, net of federal benefits

 

55,000 

 

 

226,000 

 

 

153,000 

 

 

449,000 

Non-deductible expenses

 

 —

 

 

2,000 

 

 

2,000 

 

 

7,000 

Effect of AMT expense

 

19,000 

 

 

16,000 

 

 

19,000 

 

 

16,000 

Effect of lower foreign income tax rates

 

(33,164)

 

 

(427,769)

 

 

(147,375)

 

 

(953,567)

Effect of share-based compensation

 

 —

 

 

 —

 

 

(214,000)

 

 

 —

Other

 

165,062 

 

 

 —

 

 

(39,852)

 

 

 —

Decrease in valuation allowance

 

 —

 

 

(926,862)

 

 

 —

 

 

(1,813,387)

Income tax expense

$

504,898 

 

$

116,369 

 

$

603,773 

 

$

142,046